Merck pilots diabetes SMS campaign in Africa; Pfizer filing for Xeljanz psoriasis approval; Novo teams with MLS club;

> Merck ($MRK) projects a new diabetes SMS campaign in Kenya and Uganda will reach 100,000 people annually. More

> Pfizer ($PFE) by 2015 plans to file for U.S. approval of Xeljanz as a treatment for psoriasis. News

> Sanofi ($SNY) has launched JuniorSTAR, a half-unit insulin reusable pen device that can be used with diabetes giant Lantus. Release

> Major League Soccer club the Philadelphia Union has added Novo Nordisk ($NVO) to its list of corporate partners. More

> Physicians Interactive has launched its Omnio clinical reference application for iPhone and Android. Report

> Pakistan's drug regulatory authority has asked pharma companies to provide details of the doctors and hospitals for which they have provided financial and other benefits. More

> More Pharma has launched Oculus Innovatice Sciences' ($OCLS) Microdacyn60, a treatment for mouth and throat infections, in Mexico. Release

And Finally... With healthcare reform, pharma marketers now have four different groups of targets, each of which requiring its own strategy, Bayer's former marketing VP says. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?